Your browser doesn't support javascript.
loading
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
Kreuz, W; Escuriola Ettingshausen, C; Vdovin, V; Zozulya, N; Plyushch, O; Svirin, P; Andreeva, T; Bubanská, E; Campos, M; Benedik-Dolnicar, M; Jiménez-Yuste, V; Kitanovski, L; Klukowska, A; Momot, A; Osmulskaya, N; Prieto, M; Salek, S Z; Velasco, F; Pavlova, A; Oldenburg, J; Knaub, S; Jansen, M; Belyanskaya, L; Walter, O.
Afiliação
  • Kreuz W; HZRM, Hämophilie-Zentrum Rhein Main Frankfurt-Mörfelden, Mörfelden-Walldorf, Germany.
  • Escuriola Ettingshausen C; HZRM, Hämophilie-Zentrum Rhein Main Frankfurt-Mörfelden, Mörfelden-Walldorf, Germany.
  • Vdovin V; Izmaylovo Children's Hospital Haematological Centre, Moscow, Russia.
  • Zozulya N; The State Haematological Scientific Centre RAMS, Moscow, Russia.
  • Plyushch O; The State Haematological Scientific Centre RAMS, Moscow, Russia.
  • Svirin P; Izmaylovo Children's Hospital Haematological Centre, Moscow, Russia.
  • Andreeva T; St. Petersburg State Healthcare Institution, St. Petersburg, Russia.
  • Bubanská E; Children Faculty Hospital with Policlinic, Banská Bystrica, Slovakia.
  • Campos M; Centro Hospitalar Porto, Hospital de Santo António, Porto, Portugal.
  • Benedik-Dolnicar M; Children's Hospital Oncology-Hematology Unit, University Medical Center Ljubljana, Ljubljana, Slovenia.
  • Jiménez-Yuste V; Hospital La Paz, Madrid, Spain.
  • Kitanovski L; Children's Hospital Oncology-Hematology Unit, University Medical Center Ljubljana, Ljubljana, Slovenia.
  • Klukowska A; Medical Academy, Warsaw, Poland.
  • Momot A; Altai Hematological Center, Altai, Russia.
  • Osmulskaya N; State Healthcare Institution of Omsk Region, Omsk, Russia.
  • Prieto M; Hospital General Yagüe, Castilla Leon, Spain.
  • Salek SZ; University Hospital REBRO, Zagreb, Croatia.
  • Velasco F; Hospital Reina Sofía, Córdoba, Spain.
  • Pavlova A; Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
  • Oldenburg J; Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
  • Knaub S; Octapharma AG, Lachen, Switzerland.
  • Jansen M; Octapharma Pharmazeutika Produktionsges.mbH, Vienna, Austria.
  • Belyanskaya L; Octapharma AG, Lachen, Switzerland.
  • Walter O; Octapharma AG, Lachen, Switzerland.
Haemophilia ; 22(1): 87-95, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26202305
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator VIII / Fator de von Willebrand / Anticorpos Neutralizantes / Hemofilia A / Tolerância Imunológica Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Haemophilia Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator VIII / Fator de von Willebrand / Anticorpos Neutralizantes / Hemofilia A / Tolerância Imunológica Tipo de estudo: Etiology_studies / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male Idioma: En Revista: Haemophilia Ano de publicação: 2016 Tipo de documento: Article